← Leaderboards
Anthony J. Kim
University Of Maryland Baltimore
$3,391,136
Attributed
$4,805,841
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $989.1K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,805,841 · 4
VA$0 · 1
By mechanism
R37$2,427,408 · 1
R01$1,886,274 · 1
K25$390,393 · 1
F32$101,766 · 1
I01$0 · 1
Top collaborators
- Huang Chiao Huang3 shared
- Jeffrey A Winkles3 shared
- Graeme F Woodworth3 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Vikas Kundra$4,419,746
- Huang Chiao Huang$6,185,360
- Jeffrey A Winkles$6,417,695
- Graeme F Woodworth$3,822,226
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroMemberBrainTumor Necrosis Factor ReceptorPenetrationNanoparticleFormulationBindingNeoplastic CellDrug Delivery SystemsTreatment StrategyTumor TissueTumorPharmaceutical PreparationsAffinityNeoplasm MetastasisChemotherapyFibroblast Growth FactorTissuesBreast Cancer CellEngineeringEpidermal Growth Factor ReceptorAbraxane
Grant awards (19)
Nanotherapeutic enhancement of interstitial thermal therapy for glioblastoma$634,796
R01 · FY2025 · CA
Novel drug delivery strategies for treatment of breast cancer brain metastases$0
I01 · FY2025 · VA · contact PI
Nanotherapeutic enhancement of interstitial thermal therapy for glioblastoma$603,057
R01 · FY2024 · CA
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer$330,244
R37 · FY2024 · CA · contact PI
Novel drug delivery strategies for treatment of breast cancer brain metastases$0
I01 · FY2024 · VA · contact PI
Nanotherapeutic enhancement of interstitial thermal therapy for glioblastoma$648,421
R01 · FY2023 · CA
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer$340,673
R37 · FY2023 · CA · contact PI
Novel drug delivery strategies for treatment of breast cancer brain metastases$0
I01 · FY2023 · VA · contact PI
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer$353,419
R37 · FY2022 · CA · contact PI
Novel drug delivery strategies for treatment of breast cancer brain metastases$0
I01 · FY2022 · VA · contact PI
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer$353,419
R37 · FY2021 · CA · contact PI
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer$353,419
R37 · FY2020 · CA · contact PI
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer$342,815
R37 · FY2019 · CA · contact PI
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer$353,419
R37 · FY2018 · CA · contact PI
Fn14-targeted Therapeutics for Invasive Brain Cancer$130,131
K25 · FY2016 · EB · contact PI
Fn14-targeted Therapeutics for Invasive Brain Cancer$130,131
K25 · FY2015 · EB · contact PI
Fn14-targeted Therapeutics for Invasive Brain Cancer$130,131
K25 · FY2014 · EB · contact PI
Design of Non-viral Gene Carriers that Overcome Extra- and Intracellular Barriers$43,402
F32 · FY2012 · HL · contact PI
Design of Non-viral Gene Carriers that Overcome Extra- and Intracellular Barriers$58,364
F32 · FY2011 · HL · contact PI